DECA Executive Director Terry posing for a photo with family members on a dock: wife, daughter, son-in-law, grandchild, and dog
Media Release
Read more
Diabetes camps provide summer fun and independence
DECA Executive Director Terry Ackley, and his wife, Carol, volunteered at Camp Seale Harris for several years before he was hired as the Camp’s executive director in 1995. He served in that role until joining DECA in 2012. Pictured here: Terry and Carol (right) with daughter, Emily (left), son-in-law, Patrick, and granddaughter, Vivienne.
A blue diabetes ribbon is featured with the words "celebrating 2022 a message to our TrialNet family"
Media Release
Read more
TrialNet Chair Dr. Kevan Herold reflects on 2022— “a landmark year for T1D research”
TrialNet Chair Kevan C. Herold, MD, reflects on advances in type 1 diabetes research and the need to continue testing promising treatments.
Dear TrialNet Family,
TrialNet Research Leads to FDA Approval of First Drug to Delay Type 1 Diabetes
Media Release
Read more
TrialNet Research Leads to FDA Approval of First Drug to Delay Type 1 Diabetes
Landmark findings from TrialNet research were instrumental in the Food and Drug Administration’s (FDA) November 17, 2022 approval of the first drug to delay type 1 diabetes (T1D) in people at risk.
TrialNet conducted the clinical study that discovered the immunotherapy drug teplizumab could delay T1D for 2+ years.
